OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
959456

Al-Modawat Specialized Medical Co SJSC

Healthcare Facilities & ServicesVerified

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.37, below the median for its industry, and a current ratio of 1.52, indicating moderate liquidity. However, the free cash flow of SAR 2.98 million and negative net cash position after subtracting total debt suggest limited capacity to service liabilities without external financing. Profitability metrics show a return on equity of 21.5% and return on assets of 11.8%, both exceeding the industry median for healthcare facilities. The operating margin of 18.1% (SAR 22.04 million operating income on SAR 121.82 million revenue) is strong relative to peers, though the gross margin of 43.5% (SAR 53.01 million gross profit) is in line with the sector average. The company operates as a single business unit, with all revenue derived from its hospital in Saudi Arabia. There is no disclosed geographic diversification, and the revenue concentration in one country exposes the company to local economic and regulatory risks. Outlook data is not available for the next fiscal year, but historical revenue growth is not disclosed. The capital expenditure of SAR -21.40 million suggests asset retirement or restructuring rather than expansion, which may limit future revenue potential. The risk assessment highlights medium liquidity risk due to the negative net cash position and low dilution risk. No dilutive events are disclosed in the latest filings, and the company has not issued new shares in the observed period. Recent filings and transcripts are not available in the input data, so no specific events can be cited for the current period. The company's financial disclosures are limited to the latest fiscal snapshot.

30-day price · 9594+1.12 (+27.5%)
Low$3.70High$5.30Close$5.20As of17 May, 00:00 UTC
Profile
CompanyAl-Modawat Specialized Medical Co SJSC
Ticker9594.SE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Al-Modawat Specialized Medical Co SJSC operates a hospital in Saudi Arabia, providing specialized medical services across cardiology, orthopedics, neurology, and other fields.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.37, below the median for its industry, and a current ratio of 1.52, indicating moderate liquidity. However, the free cash flow of SAR 2.98 million and negative net cash position after subtracting total debt suggest limited capacity to service liabilities without external financing. Profitability metrics show a return on equity of 21.5% and return on assets of 11.8%, both exceeding the industry median for healthcare facilities. The operating margin of 18.1% (SAR 22.04 million operating income on SAR 121.82 million revenue) is strong relative to peers, though the gross margin of 43.5% (SAR 53.01 million gross profit) is in line with the sector average. The company operates as a single business unit, with all revenue derived from its hospital in Saudi Arabia. There is no disclosed geographic diversification, and the revenue concentration in one country exposes the company to local economic and regulatory risks. Outlook data is not available for the next fiscal year, but historical revenue growth is not disclosed. The capital expenditure of SAR -21.40 million suggests asset retirement or restructuring rather than expansion, which may limit future revenue potential. The risk assessment highlights medium liquidity risk due to the negative net cash position and low dilution risk. No dilutive events are disclosed in the latest filings, and the company has not issued new shares in the observed period. Recent filings and transcripts are not available in the input data, so no specific events can be cited for the current period. The company's financial disclosures are limited to the latest fiscal snapshot.
Key takeaways
  • The company has strong profitability metrics, with ROE and ROA above industry medians.
  • Liquidity is moderate, with a current ratio of 1.52 and negative net cash after debt.
  • The business is concentrated in Saudi Arabia, with no geographic diversification.
  • Capital expenditures suggest asset retirement or restructuring rather than growth.
  • Dilution risk is low, with no recent share issuance or dilutive events disclosed.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$121.8M
Gross profit$53.0M
Operating income$22.0M
Net income$19.0M
R&D
SG&A
D&A
SBC
Operating cash flow$4.3M
CapEx-$21.4M
Free cash flow$3.0M
Total assets$160.8M
Total liabilities$72.6M
Total equity$88.3M
Cash & equivalents
Long-term debt$32.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$88.3M
Net cash-$32.5M
Current ratio1.5
Debt/Equity0.4
ROA11.8%
ROE21.5%
Cash conversion23.0%
CapEx/Revenue-17.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric9594Activity
Op margin18.1%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin15.6%14.7% medp25 11.7% · p75 28.1%above median
Gross margin43.5%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-17.6%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity37.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 08:04 UTC#de1fb0a4
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 08:06 UTCJob: b07a1a7c